Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients

STATUS

Recruiting
participants needed

25
sponsor

SOLTI Breast Cancer Research Group

Send

Updated on 19 February 2024

See if I qualify

cancer

glycosylated hemoglobin

breast cancer

platelet count

absolute neutrophil count

metastasis

gilbert's syndrome

neutrophil count

glomerular filtration rate

anticoagulation therapy

taxane

formalin-fixed paraffin-embedded

progressive disease

adenocarcinoma

ipatasertib

ejection fraction

bone metastases

invasive breast cancer

trastuzumab

adenocarcinoma of the breast

pertuzumab

diarrhea

serum bilirubin

metastatic adenocarcinoma

adjuvant therapy

aptt

stage iv breast cancer

breast adenocarcinoma

her2/neu-positive breast cancer

bilateral breast cancer

serum bilirubin level

ffpe

pik3ca

hcg pregnancy test

her2-positive breast cancer

immunological adjuvant

adjuvant

HER2

her2 positive breast carcinoma

Summary

This is an open label, single arm, multicenter, phase Ib study to evaluate the safety and clinical activity of the combination of ipatasertib, trastuzumab and pertuzumab in patients with unresectable locally advanced or metastatic HER2-positive breast cancer with tumors harboring PIK3CA mutations, candidates to receive maintenance HP after first line treatment for metastatic disease with a taxane plus HP

Description

The main objective of the study is to assess whether the combination of ipatasertib and HP (+/- ET) is tolerable, especially in terms of the incidence and severity of diarrhea. For this purpose, up to a total of 25 patients will be enrolled in a staggered manner and evaluated.

A 3-cohort, descending doses (400, 300, 200 mg) design will serve to establish the Maximun Toleraded Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ipatasertib in combination with HP.

The study will initially include 6 patients that will receive ipatasertib plus HP at Dose Level 1.

If 1 DLTs are observed, this dose will be deemed safe, and the trial will enroll at least additional 19 patients to further assess safety and preliminary efficacy of the combination.

If 2 DLT occurs in the first 6 patients, a decision will be made of whether expand Dose Level 1 to 10 additional patients or to de-escalate ipatasertib to the next lower dose level. In the case of de-escalation, the same rules will apply for enrollment and expansion of Dose level -1. The minimum ipatasertib dose explored will be Dose level -2.

Dose reductions of pertuzumab and trastuzumab will not be allowed.

If all inclusion criteria and no exclusion criteria are met, patients will be enrolled in the trial and will start treatment with oral (PO) ipatasertib once a day (QD) D1-21 in 28-days cycles, together with pertuzumab 420 mg intravenous (IV) every 21 days (Q21d) and trastuzumab 600 mg subcutaneous (SC) Q21d.

Patients with hormone receptor positive (HR+) tumors (defined as ER and/or PgR expression in >1% of tumor cells) will also receive endocrine therapy either an Aromatase Inhibitor (AI), tamoxifen or fulvestrant +/- Luteinizing Hormone-Releasing Hormone (LHRH) analogues, according to Investigator's decision.

Patients will also start loperamide (2 mg twice a day [BID] or 4 mg QD) as prophylaxis for diarrhea in the first cycle

Details

Condition	Metastatic Breast Cancer
Age	18years - 100years
Treatment	Trastuzumab, Ipatasertib, Pertuzumab
Clinical Study Identifier	NCT04253561
Sponsor	SOLTI Breast Cancer Research Group
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	b'Written and signed informed consent for all study procedures according to local'
	b'regulatory requirements prior to beginning of specific protocol procedures.'
	b'Female (pre- or postmenopausal) or male patients.'
	b'Age \\u2265 18 years.'
	b'Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.'
	b'Confirmed HER2-positive invasive breast cancer by central determination defined by'
	b'American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP)'
	b'clinical practice guidelines. (Wolff el al. Arch Pathol Lab Med-Vol 142, November'
	b'2018;).'
	b'Known hormone receptor status, as assessed locally, defined by ASCO/CAP clinical'
	b'practice guidelines. ER/PR positivity is defined as the presence of \\u2265 1% of tumor'
	b'cells with nuclear staining (Hammond et al. JCO 2010).'
	b'Histologically confirmed, locally advanced or metastatic adenocarcinoma of the breast.'
	b'Patients with unresectable locally advanced disease must have recurrent or'
	b'progressive disease, which must not be amenable to resection with curative'
	b'intent. Patients with available standard curative options are not eligible.'
	b'For patients with bilateral breast cancer, HER2-positivity must be demonstrated'
	b'in both locations or in a metastatic biopsy.'
	b'Patient must be a candidate to receive maintenance HP after first line treatment for'
	b'metastatic disease with at least 4 cycles of taxane plus HP.'
	b'Prior taxane must have been discontinued for a reason other than progressive disease.'
	b'Patients may or may not have received neo/adjuvant therapy but must have a'
	b'disease-free interval from completion of anti-HER2 therapy to metastatic diagnosis \\u22656'
	b'months.'
	b'PIK3CA mutation identified and confirmed in tumor tissue or plasma ctDNA by central'
	b'determination.'
	b'Start of treatment with ipatasertib plus HP no later than 9 weeks after last dose of'
	b'taxane plus HP (i.e., maximum of 2 HP administrations with no taxane).'
	b'Willingness and ability to provide archived formalin fixed paraffin embedded (FFPE)'
	b'tissue block.'
	b'Measurable or non-measurable (but evaluable) disease, as per RECIST 1.1 criteria.'
	b'No baseline diarrhea or diarrhea grade \\u22641 within the last 28 days.'
	b'Adequate hematologic and organ function within 14 days before the first study'
	b'treatment on Day 1 of Cycle 1, defined by the following:'
	b'Neutrophils (ANC \\u22651500/\\u03bcL)'
	b'Hemoglobin \\u22659 g/dL (with no need for transfusions in the last 14 days).'
	b'Platelet count \\u226575,000/\\u03bcL'
	b'Serum albumin \\u22653 g/dL'
	b'Total bilirubin \\u22641.5x the upper limit of normal (ULN), with the exception:'
	b'patients with known Gilbert syndrome who have serum bilirubin \\u22643x ULN.'
	b'AST and ALT \\u22642.5x ULN, with the following exception: patients with documented'
	b'liver or bone metastases who may have AST and ALT \\u22645x ULN.'
	b'ALP \\u22642x ULN, with the following exceptions:'
	b'Patients with known liver involvement who may have ALP \\u22645x ULN.'
	b'Patients with known bone involvement who may have ALP \\u22647x ULN.'
	b'PTT (or aPTT) and INR \\u22641.5x ULN (except for patients receiving anticoagulation'
	b'therapy).'
	b'Patients receiving heparin treatment should have a PTT (or aPTT) between 1.5'
	b'and 2.5x ULN.'
	b'Patients receiving coumarin derivatives should have an INR between 2.0 and'
	b'0 assessed in two consecutive measurements 1 to 4 days apart.'
	b'Serum creatinine <1.5x ULN or creatinine clearance \\u226550 mL/min based on'
	b'Cockcroft\\u2212Gault glomerular filtration rate estimation:'
	b'(140 \\u2212 age) x (weight in Kg) x 0.85 (if female)/72 x (serum creatinine in mg/dL)'
	b'Fasting total serum glucose \\u2264150mg/dL and glycosylated hemoglobin (HbA1C) \\u22647.5%'
	b'Life expectancy of at least 6 months.'
	b'Baseline left ventricular ejection fraction (LVEF) \\u226550% measured by echocardiography'
	b'(ECHO) or Multiple Gate Acquisition (MUGA) scan.'
	b'Negative \\u03b2-HCG pregnancy test (serum) for premenopausal women of reproductive capacity'
	b'(those who are biologically capable of having children) and for women less than 12'
	b'months after the menopause. All subjects who are biologically capable of having'
	b'children must agree and commit to the use of a reliable method of birth control from 2'
	b'weeks before administration of the first dose of investigational product until 28 days'
	b'after the last dose of investigational product.'
	b'Absence of any psychological, familial, sociological or geographical condition'
	b'potentially hampering compliance with the study protocol and follow-up schedule; those'
	b'conditions should be discussed with the patient before registration in the trial.'
Exclusion Criteria
	b'Last dose of taxane plus HP given more than 9 weeks prior to C1D1.'
	b'Prior malignancy within 3 years prior to randomization, except curatively treated'
	b'non-melanoma skin, carcinoma in situ of the cervix or Stage I uterine cancer.'
	b'Brain metastases that have not been treated previously, are progressive, or require'
	b'any type of therapy (e.g., radiation, surgery, or steroids) to control symptoms within'
	b'30 days prior to the first study treatment dose.'
	b'Radiotherapy for metastatic sites of disease outside of the brain performed within 14'
	b'days prior to study enrollment and/or radiation of >30% of marrow-bearing bone.'
	b'Symptomatic hypercalcemia requiring use of bisphosphonate or RANKL inhibitors therapy'
	b'within 21 days prior to the first study treatment. Patients who receive bisphosphonate'
	b'therapy specifically to prevent skeletal events are eligible if they have been'
	b'initiated prior to the treatment to study.'
	b'Cardiopulmonary dysfunction as defined by:'
	b'Inadequately controlled angina or serious cardiac arrhythmia not controlled by'
	b'adequate medication.'
	b'Inadequate LVEF at baseline, as defined as LVEF <50% by either ECHO or MUGA scan.'
	b'History of symptomatic congestive heart failure (CHF): Grade \\u22653 per NCI CTCAE'
	b'version 4.03 or Class \\u2265II New York Health Association (NYHA) criteria.'
	b'History of a decrease in LVEF to <40% or symptomatic CHF with prior trastuzumab'
	b'or HP treatment.'
	b'History of myocardial infarction within 6 months prior to randomization.'
	b'Current dyspnea at rest due to complications of advanced malignancy, or other'
	b'disease requiring continuous oxygen therapy.'
	b"Congenital long QT syndrome or screening QT interval corrected using Fridericia's"
	b'formula (QTcF) > 480 milliseconds.'
	b'Concurrent, serious, uncontrolled infections or current known infection with HIV'
	b'(testing is not mandatory).'
	b'History of intolerance, including Grade 3-4 infusion reaction or hypersensitivity, to'
	b'trastuzumab or pertuzumab.'
	b'Known hypersensitivity to any of the study drugs, including excipients.'
	b'Known clinically significant history of liver disease consistent with Child-Pugh Class'
	b'B or C, including active viral or other hepatitis (e.g., positive for hepatitis B'
	b'urface antigen [HBsAg] or hepatitis C virus [HCV] antibody at screening), current'
	b'drug or alcohol abuse, or cirrhosis.'
	b'Patients with past hepatitis B virus (HBV) infection or resolved HBV infection'
	b'(defined as having a negative HBsAg test and a positive antibody to hepatitis B'
	b'core antigen [HBcAg] antibody test) are eligible.'
	b'Patients positive for HCV antibody are eligible only if polymerase chain reaction'
	b'(PCR) is negative for HCV RNA'
	b'History of Type I or Type II diabetes mellitus requiring insulin. Patients who are on'
	b'table dose of oral diabetes medication > 2 weeks prior to initiation of study'
	b'treatment are eligible for enrollment.'
	b'Grade \\u22652 uncontrolled or untreated hypercholesterolemia or hypertriglyceridemia.'
	b"History of or active inflammatory bowel disease (e.g., Crohn's disease and ulcerative"
	b'colitis) or active bowel inflammation (e.g., diverticulitis).'
	b'Lung disease: pneumonitis, interstitial lung disease, idiopathic pulmonary fibrosis,'
	b'cystic fibrosis, Aspergillosis, active tuberculosis, or history of opportunistic'
	b'infections (Pneumocystis pneumonia or Cytomegalovirus pneumonia).'
	b'Need for chronic corticosteroid therapy of >10 mg of prednisone per day or an'
	b'equivalent dose of other anti-inflammatory corticosteroids for a chronic disease.'
	b'Uncontrolled pleural effusion, pericardial effusion, or ascites. Patients with'
	b'indwelling catheters (e.g., PleurX\\xae) are allowed.'
	b'Treatment with strong CYP3A inhibitors or strong CYP3A inducers within 2 weeks or 5'
	b'drug-elimination half-lives, whichever is longer, prior to initiation of study drug.'
	b'Prior treatment with an AKT inhibitor. Prior PI3K or mTOR inhibitors are allowed.'
	b'Current severe, uncontrolled systemic disease (e.g. clinically significant'
	b'cardiovascular, pulmonary or metabolic disease; wound healing disorders; ulcers; bone'
	b'fractures).'
	b'Unresolved, clinically significant toxicity from prior therapy, except for alopecia'
	b'and Grade 1 peripheral neuropathy.'
	b'Major surgical procedure or significant traumatic injury within 28 days prior to'
	b'enrollment.'
	b'Assessment by the investigator to be unable or unwilling to comply with the'
	b'requirements of the protocol.'
	b'History of significant comorbidities that, in the judgment of the investigator, may'
	b'interfere with the conduction of the study, the evaluation of response, or with'
	b'informed consent.'

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

cancer

glycosylated hemoglobin

breast cancer

platelet count

absolute neutrophil count

metastasis

gilbert's syndrome

neutrophil count

glomerular filtration rate

anticoagulation therapy

taxane

formalin-fixed paraffin-embedded

invasive breast cancer

trastuzumab

adenocarcinoma of the breast

pertuzumab

diarrhea

serum bilirubin

metastatic adenocarcinoma

adjuvant therapy

aptt

stage iv breast cancer

breast adenocarcinoma

her2/neu-positive breast cancer

bilateral breast cancer

serum bilirubin level

ffpe

pik3ca

hcg pregnancy test

her2-positive breast cancer

immunological adjuvant

adjuvant

HER2

her2 positive breast carcinoma

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients